Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer – a single institution retrospective analysis

BACKGROUND: KRAS mutation status in codons 12 and 13 is recognized as a predictive factor for resistance to anti-EGFR monoclonal antibodies. Despite having a wild type KRAS (wt-KRAS), not all patients with wt-KRAS respond to anti-EGFR antibody treatment. Additional mechanisms of resistance may activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebersek, Martina, Boc, Marko, Cerkovnik, Petra, Benedik, Jernej, Hlebanja, Zvezdana, Volk, Neva, Novakovic, Srdjan, Ocvirk, Janja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Versita, Warsaw 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423757/
https://www.ncbi.nlm.nih.gov/pubmed/22933967
http://dx.doi.org/10.2478/v10019-011-0039-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423757/
https://www.ncbi.nlm.nih.gov/pubmed/22933967
http://dx.doi.org/10.2478/v10019-011-0039-y

Ejemplares similares